Globally, breast cancer is the most abundant cancer form in women, in Sweden about 20 women are diagnosed with breast cancer every day .Interactions between genetic and external factors are the contributing factors while metastasis formation is the leading cause of death. Cancer is in need of vessels,to get the nutrients and oxygen it needs in order to survive. Therefore,the aim of the study is to analyze and compare the groups of high and low differential cancer vessels of the respective form, and to see if any type contained more vessels than the other. The study is based on 20 invasive ductal breast cancer samples, ten of them were high differentiated and the other ten were low differentiated. To assess the number of vessels, immunhistochemical staining with CD31 antibody was performedCD31 is an adhesion molecule present on endothelial cells. The group of low differentiated gradebreast cancer tissue had significantly more vessels compared with the high differentiated breast cancer tissues. To prove these test results, more cancers must be analyzed.

Angiogenesis has a crucial influence on tumour development and identification of microvessels in malignant breast cancer tissue is an indicator for worse prognosis. Angiogenesis is partially governed by the family of vascular endothelial growth factors (VEGF) and their receptors, by which the VEGF-A-protein seems to be the most important factor.     The aims of this work were to first establish a method for immunohistological (IH)-staining of the VEGF-A-protein for clinical use and then to label and evaluate the expression of this protein in 31 Nottingham Histology Graded (NHG I-III) breast carcinoma.      Formaldehyde-fixated tissues from invasive breast neoplasms and control tissues were labelled with monoclonal antibodies against VEGF-A and CD31-proteins using a semi-automated IH-system from Ventana BenchMark. Positively stained vessels were counted from digital copies of microscopic pictures related to mm2 tissue.     A method of IH-labelling with VEGF-A protein was successfully established before staining of the breast tissue and in 19 of the 31 breast cancers. Vessels were counted for both antibodies. The VEGF-A-antibody stained 2.7 ± 2.3 (mean ± SD) vessels/mm2 and the CD31-antibody stained 27.3 ± 19.3 in the breast carcinoma tissue. The percent of VEGF-A-stained vessels in relation to CD31-stained were 7.6% in the NHG-I- (n=3), 7.8% in the NHG-II- (n=10) and 15.0% in the NHG-III-group (n=6).     The results demonstrate that increased NHG-grade and lower differentiation can be associated with higher percent of vessels expressing VEGF-A-protein. The result was not statistically certified because of the small number of stained breast cancers and additional investigations are recommended before clinical use.

BACKGROUND:Primary cilia are microtubule-based organelles that protrude from the cell surface. Primary cilia play a critical role in development and disease through regulation of signaling pathways including the Hedgehog pathway. Recent mouse models have also linked ciliary dysfunction to cancer. However, little is known about the role of primary cilia in breast cancer development. Primary cilia expression was characterized in cancer cells as well as their surrounding stromal cells from 86 breast cancer patients by counting cilia and measuring cilia length. In addition, we examined cilia expression in normal epithelial and stromal cells from reduction mammoplasties as well as histologically normal adjacent tissue for comparison.RESULTS:We observed a statistically significant decrease in the percentage of ciliated cells on both premalignant lesions as well as in invasive cancers. This loss of cilia does not correlate with increased proliferative index (Ki67-positive cells). However, we did detect rare ciliated cancer cells present in patients with invasive breast cancer and found that these express a marker of basaloid cancers that is associated with poor prognosis (Cytokeratin 5). Interestingly, the percentage of ciliated stromal cells associated with both premalignant and invasive cancers decreased when compared to stromal cells associated with normal tissue. To understand how cilia may be lost during cancer development we analyzed the expression of genes required for ciliogenesis and/or ciliary function and compared their expression in normal versus breast cancer samples. We found that expression of ciliary genes were frequently downregulated in human breast cancers.CONCLUSIONS:These data suggest that primary cilia are lost early in breast cancer development on both the cancer cells and their surrounding stromal cells.

Background: Black South African women are known to have a high usage rate of injectable contraceptives. Breast cancer is the second leading cancer after malignant cervical neoplasms in black South African women. There is evidence that sex hormones are associated with an increased risk of developing breast cancer. In the Western Cape, investigators suggested that injectable contraceptives, more specifically DMPA, may increase breast cancer risk. In another study conducted in the same province, a weak association between breast cancer and women taking combined oestrogen/progesterone oral contraceptives was found, though no risk associated with injectable progestogen contraceptives (DMPA) was confirmed. Study Objective: This study aimed to determine whether there is an association between hormonal contraceptive use and an increased risk of cancer of the breast. Methods: Data was obtained from an ongoing case control study set up by MRC/Wits/NHLS Cancer Epidemiology Research Group (CERG) in 1995 to investigate risk factors associated with cancer among the black population in Johannesburg. Data was processed using STATA, version8 and analysed using univariate, bivariate and multivariate unmatched logistic regression models. Results: There was evidence that an overall use of oral contraceptives increases the risk of breast cancer; cases (n= 221), controls :( n= 153), OR=2.01 (95% CI:1.45, 2.80), p<0.0001. There was evidence of an association between use of injectable contraception and the risk of breast cancer; cases (n=244), controls (n=202), OR=1.51(CI: 1.14, 2.01),p=0.004 Surprisingly, no other use characteristic of either hormonal contraceptive method was statistically significantly associated with the risk of breast cancer in our dataset. The combined use of both oral and injectable contraception was associated with an increased risk of breast cancer, OR=1.68(1.21, 2.33), p =0.002. There was a strong effect modification (interaction) between oral contraceptive use and injectable progesterone associated with the risk of breast cancer, (p=0.008). Conclusion: After adjusting for all potential risk and confounding factors, as collected in the dataset, there was evidence of an association between combined oral contraceptive use and breast cancer. An association between cancer of the breast and overall use of injectable progesterone use was also established. There was evidence of association between the use of both hormonal contraceptive methods and an increased risk of breast cancer. However, whether these findings reflect the reality in terms of causal relationship or are the result of bias must be ascertained.

Changes in the microenvironment have been implicated in the transition of pre-invasive ductal carcinoma in-situ (DCIS) to invasive breast cancer. Normal myoepithelial cells have a tumour suppressor phenotype but they are altered in DCIS and ultimately lost with transition to invasive cancer. A consistent change in DCIS is up-regulation of the integrin αvβ6 in myoepithelial cells. Preliminary observations identified a correlation between myopeithelial αvβ6 and an increased peri-ductal inflammatory infiltrate. The hypothesis of this study is that the altered myoepithelial phenotype influences the peri-ductal inflammatory environment, which in turn mediates a pro-apoptotic effect on myoepithelial cells contributing to their loss. To investigate this, the inflammatory infiltrate was characterised in a series of DCIS tissue in relation to αvβ6 status. This demonstrated significantly higher levels of CD4+ve and FOXP3+ve T cells around αvβ6+ve DCIS ducts compared to αvβ6-ve ducts (P=<0.01), suggesting an increase in Treg cells. In-vivo, Matrigel plugs containing injected into the flanks of female C57/Blk6 normal mice generated influx of higher levels of CD4+ve cells (p=0.005) and FOXP3+ T cells (p=0.007) in the presence of αvβ6+ve myoepithelial cells compared to αvβ6-ve cells, supporting the findings in human tissue samples. Since Treg cells produce TRAIL that can induce apoptosis, we investigated the influence of αvβ6 on myoepithelial cells on the levels of TRAIL in T cells and the hypothesis that αvβ6-positive myoepithelial ells may be more susceptible to TRAIL-induced apoptosis, leading to loss of the myoepithelial barrier. Firstly, levels of TRAIL in Jurkat and primary T cell populations co-cultured with β4 (ii) or β6 myoepithelial cells were measured. This demonstrated a higher level of TRAIL in primary T cells co-cultured β6 myoepithelial cells compared to those co-cultured with β4 myoepithelial cells. β6+ve and β6-ve myoepithelial cells were exposed to TRAIL, and this demonstrated that TRAIL enhanced apoptosis, measured by cleaved PARP, in β6+ve cells. Furthermore, these cells showed loss of the anti-apoptotic protein Galectin-7, and knockdown of Galectin-7 in normal β6-ve myoepithelial cells rendered them more susceptible to TRAIL-induced apoptosis. In DCIS tissues, an inverse relationship between αvβ6 and Galectin-7 in myoepithelial cells was demonstrated, and Cytokine Array analysis showed that αvβ6+ve myoepithelial cells express higher levels of IL-16, which has a role in Treg cell recruitment. Taken together these results suggest that expression of αvβ6 by myoepithelial cells in DCIS generates a tumour-promoter peri-ductal inflammatory infiltrate through altered cytokine release, is associated with reduced galectin-7 expression and enhances myoepithelial cell apoptosis in response to TRAIL. This provides a potential mechanism by which myoepithelial cells may be lost during evolution of DCIS and so contribute to progression to invasive disease.

Deux tiers des cancers du sein expriment des récepteurs hormonaux ostrogéniques (tumeur ER-positive) et la croissance de ces tumeurs est stimulée par l’estrogène. Des traitements adjuvant avec des anti-estrogènes, tel que le Tamoxifen et les Inhibiteurs de l’Aromatase peuvent améliorer la survie des patientes atteinte de cancer du sein. Toutefois la thérapie hormonale n’est pas efficace dans toutes les tumeurs mammaires ER-positives. Les tumeurs peuvent présenter avec une résistance intrinsèque ou acquise au Tamoxifen. Présentement, c’est impossible de prédire quelle patiente va bénéficier ou non du Tamoxifen. Des études préliminaires du laboratoire de Dr. Mader, ont identifié le niveau d’expression de 20 gènes, qui peuvent prédire la réponse thérapeutique au Tamoxifen (survie sans récidive). Ces marqueurs, identifié en utilisant une analyse bioinformatique de bases de données publiques de profils d’expression des gènes, sont capables de discriminer quelles patientes vont mieux répondre au Tamoxifen. Le but principal de cette étude est de développer un outil de PCR qui peut évaluer le niveau d’expression de ces 20 gènes prédictif et de tester cette signature de 20 gènes dans une étude rétrospective, en utilisant des tumeurs de cancer du sein en bloc de paraffine, de patients avec une histoire médicale connue. Cet outil aurait donc un impact direct dans la pratique clinique. Des traitements futiles pourraient être éviter et l’indentification de tumeurs ER+ avec peu de chance de répondre à un traitement anti-estrogène amélioré. En conséquence, de la recherche plus appropriée pour les tumeurs résistantes au Tamoxifen, pourront se faire. / Two thirds of breast cancers express the estrogen receptor (ER-positive tumours) and estrogens stimulate growth of these tumours. Adjuvant therapy with anti-estrogens such as Tamoxifen and Aromatase Inhibitors has been shown to increase survival in breast cancer patients. This treatment is, however, not successful in all ER-positive tumours. Tumours can present intrinsic or acquired resistance to Tamoxifen. However, it is currently impossible to predict which patient will benefit from Tamoxifen therapy and which will not. Preliminary studies in Dr. Mader’s lab have identified 20 genes whose expression levels in tumours are able to predict the response to Tamoxifen therapy (disease-free survival). These markers, identified using bioinformatics analysis of published gene expression datasets, were able to discriminate patients that would respond best to Tamoxifen from those that did not. The overall purpose of this study is to develop a PCR kit to monitor expression levels of these 20 genes and to test this 20-gene signature in a retrospective study using paraffin-embedded breast cancer tissues of patients with a known medical history. This tool may thus have a direct impact on clinical practice through the development of markers of therapeutic success for treatment with Tamoxifen and possibly Aromatase Inhibitors. Futile treatments would be avoided thus preventing needless side effects, and improved identification of ER+ tumours with a low chance of success to anti-estrogen therapy. This will facilitate research into more appropriate treatments for hormone resistant tumours.

Deux tiers des cancers du sein expriment des récepteurs hormonaux ostrogéniques (tumeur ER-positive) et la croissance de ces tumeurs est stimulée par l’estrogène. Des traitements adjuvant avec des anti-estrogènes, tel que le Tamoxifen et les Inhibiteurs de l’Aromatase peuvent améliorer la survie des patientes atteinte de cancer du sein. Toutefois la thérapie hormonale n’est pas efficace dans toutes les tumeurs mammaires ER-positives. Les tumeurs peuvent présenter avec une résistance intrinsèque ou acquise au Tamoxifen. Présentement, c’est impossible de prédire quelle patiente va bénéficier ou non du Tamoxifen. Des études préliminaires du laboratoire de Dr. Mader, ont identifié le niveau d’expression de 20 gènes, qui peuvent prédire la réponse thérapeutique au Tamoxifen (survie sans récidive). Ces marqueurs, identifié en utilisant une analyse bioinformatique de bases de données publiques de profils d’expression des gènes, sont capables de discriminer quelles patientes vont mieux répondre au Tamoxifen. Le but principal de cette étude est de développer un outil de PCR qui peut évaluer le niveau d’expression de ces 20 gènes prédictif et de tester cette signature de 20 gènes dans une étude rétrospective, en utilisant des tumeurs de cancer du sein en bloc de paraffine, de patients avec une histoire médicale connue. Cet outil aurait donc un impact direct dans la pratique clinique. Des traitements futiles pourraient être éviter et l’indentification de tumeurs ER+ avec peu de chance de répondre à un traitement anti-estrogène amélioré. En conséquence, de la recherche plus appropriée pour les tumeurs résistantes au Tamoxifen, pourront se faire. / Two thirds of breast cancers express the estrogen receptor (ER-positive tumours) and estrogens stimulate growth of these tumours. Adjuvant therapy with anti-estrogens such as Tamoxifen and Aromatase Inhibitors has been shown to increase survival in breast cancer patients. This treatment is, however, not successful in all ER-positive tumours. Tumours can present intrinsic or acquired resistance to Tamoxifen. However, it is currently impossible to predict which patient will benefit from Tamoxifen therapy and which will not. Preliminary studies in Dr. Mader’s lab have identified 20 genes whose expression levels in tumours are able to predict the response to Tamoxifen therapy (disease-free survival). These markers, identified using bioinformatics analysis of published gene expression datasets, were able to discriminate patients that would respond best to Tamoxifen from those that did not. The overall purpose of this study is to develop a PCR kit to monitor expression levels of these 20 genes and to test this 20-gene signature in a retrospective study using paraffin-embedded breast cancer tissues of patients with a known medical history. This tool may thus have a direct impact on clinical practice through the development of markers of therapeutic success for treatment with Tamoxifen and possibly Aromatase Inhibitors. Futile treatments would be avoided thus preventing needless side effects, and improved identification of ER+ tumours with a low chance of success to anti-estrogen therapy. This will facilitate research into more appropriate treatments for hormone resistant tumours.